References
- NICE clinical guideline 85 Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension. Available at: http://www.nice.org.uk/nicemedia/live/12145/43839/43839.pdf (Last accessed 2 November 2010)
- Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297-304
- European medicine agency Brinzolamide Doc. Ref: EMA/793685/2009 EMEA/H/C/267. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000267/WC500030360.pdf (Last accessed 2 November 2010)
- Shoji N, Ogata H, Suyama H, et al. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Curr Med Res Opin 2005;21:503-8
- Abe K, Kashiwagi K. Additive effect of brinzolamide on diurnal changes in intraocular pressure in latanoprost-treated eyes. Open Ophthalmol J 2008;2:160-4
- Miura K, Ito K, Okawa C, et al. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost. J Glaucoma 2008;17:233-7
- Day DG, Hollander DA. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Curr Med Res Opin 2008;24:1435-42
- Bournias TE, Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Ophthalmology 2009;116:1719-24
- Nakamura Y, Ishikawa S, Nakamura Y, et al. 24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost. Clin Ophthalmol 2009;3:395-400
- Rahman MQ, Montgomery DM, Lazaridou MN. Surveillance of glaucoma medical therapy in a Glasgow teaching hospital: 26 years’ experience. Br J Ophthalmol 2009;93:1572-5
- Leskea MC, Heijl A, Hyman L, et al. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr Opin Ophthalmol 2004;15:102-6
- Sall K. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Surv Ophthalmol 2000;44(Suppl 2):S155-62